VO2 CAP HOLDING AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.86 SEK | -1.38% |
|
-2.39% | -2.05% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.7 for the 2024 fiscal year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company benefits from high valuations in earnings multiples.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -2.05% | 14.3M | - | ||
| +5.87% | 32.95B | C | ||
| +21.57% | 7.82B | C- | ||
| +32.81% | 4.17B | B- | ||
| -27.79% | 2.72B | C- | ||
| -32.48% | 1.15B | - | ||
| +10.53% | 980M | C | ||
| -36.79% | 873M | - | ||
| -28.50% | 831M | - | C+ | |
| -15.67% | 688M | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- VO2 Stock
- Ratings Vo2 Cap Holding AB